American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Amazon Explores AI Content Marketplace With Media Publishers 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
REDWOOD CITY, Calif, Nov. 02, 2017 -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report third quarter 2017 financial results after market close on Thursday, November 9, 2017. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss financial results and provide a company update.
| Live Call: | U.S. | 855 890 8665 | ||||
| International | 720 634 2938 | |||||
| Passcode | 5797258 | |||||
| Live Webcast: | Codexis IR Website | |||||
| The webcast will be archived for 30 days. | ||||||
| Replay: | U.S. | 855 859 2056 | ||||
| International | 404 537 3406 | |||||
| Passcode | 5797258 | |||||
| The replay will be available for 48 hours | ||||||
About Codexis, Inc.
Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for commercial manufacture of pharmaceuticals and fine chemicals, as well as the development of enzymes as biotherapeutics and for molecular diagnostics. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, see www.codexis.com.
CONTACTS
Investors
LHA Investor Relations
Jody Cain, 310 691 7100
[email protected]
